In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% ...
Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...
Bulls N’ Bears ASX Runner of the Week is… Kalgoorlie Gold Mining. The company’s share price rocketed after it made a WA gold ...
Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback